Citi Raises Gilead (GILD) Price Target Ahead of Q1 Biopharma Preview [Yahoo! Finance]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Yahoo! Finance
On April 13, Citi analyst Geoff Meacham lifted the firm's price recommendation on Gilead Sciences, Inc. (NASDAQ:GILD) to $165 from $156. It reiterated a Buy rating on the shares. The update came as part of a broader Q1 preview in the biopharma space. On April 7, Reuters reported that Gilead said it would acquire Germany-based Tubulis GmbH for up to $5 billion, as it looks to strengthen its cancer drugs pipeline. The move adds to Gilead's recent deal activity. The company has been pushing beyond its core areas as it faces patent expiries and weaker sales from its COVID-19 treatment. With this acquisition, Gilead gains access to Tubulis' experimental drugs. These are part of a class known as antibody-drug conjugates, or ADCs, often described as “guided missiles” because they deliver chemotherapy directly to cancer cells while limiting damage to healthy tissue. Gilead will acquire all outstanding equity of Tubulis for $3.15 billion in upfront cash, payable at closing, along with up
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Jim Cramer on Gilead Sciences: “I'd Hold On to It” [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences (GILD) had its price target raised by The Goldman Sachs Group, Inc. from $125.00 to $130.00. They now have a "neutral" rating on the stock.MarketBeat
- Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender OfferBusiness Wire
- Gilead Sciences' HIV Drug Shows Weaker-Than-Expected Persistence Nine Months After Launch, RBC Says [Yahoo! Finance]Yahoo! Finance
- Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer [Yahoo! Finance]Yahoo! Finance
GILD
Earnings
- 2/10/26 - Beat
GILD
Sec Filings
- 4/16/26 - Form 4
- 4/16/26 - Form 4
- 4/15/26 - Form 144
- GILD's page on the SEC website